Aerosolization of tobramycin (TOBI®) with the PARI LC PLUS® reusable nebulizer: Which compressor to use? Comparison of the CR60® to the PortaNeb® compressor

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 21, Issue 3, 2008, Pages 269-280

  Westerman, Elsbeth M ^a,b   Boer, Anne H De ^c   Touw, Daan J ^a,b   Brun, Paul P H Le ^a,b   Roldaan, Albert C ^b   Frijlink, Henderik W ^c   Heijerman, Harry G M ^b  

^a Apotheek Haagse Ziekenhuizen   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Clinical trial; Compressor; Cystic fibrosis; Nebulizer; TOBI

Indexed keywords

BRONCHODILATING AGENT; COLISTIMETHATE; TOBRAMYCIN;

ADULT; AEROSOL; AIRWAY; ARTICLE; CHEST TIGHTNESS; CLINICAL ARTICLE; COMPRESSOR; CYSTIC FIBROSIS; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL APPARATUS, EQUIPMENT AND SUPPLIES; HUMAN; LUNG FUNCTION; MALE; NEBULIZATION; NEBULIZER; QUESTIONNAIRE; RISK; SIDE EFFECT; TOXICITY;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYSTIC FIBROSIS; EQUIPMENT DESIGN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PATIENT SATISFACTION; PILOT PROJECTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; SOLUTIONS; TISSUE DISTRIBUTION; TOBRAMYCIN; YOUNG ADULT;

EID: 54949110567     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2007.0674     Document Type: Article

References (43)

1. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
2. Hodson ME, Gallagher CG, Govan JR: A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-664.
3. Taylor RF, Morgan DW, Nicholson PS, Mackay IS, Hodson ME, Pitt TL. Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis. Thorax 1992;47:426-428.
4. Tiddens HAWM: Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 2002;34:228-231.
5. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Doring G: Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-325.
6. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005;172:1497-1504.
7. Novartis Pharma B.V. A, The Netherlands. Product information TOBI® (Samenvatting van de produktkenmerken). 2006.
8. de Boer AH, Hagedoorn P, Frijlink HW: The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser. Int J Pharm 2003;268:59-69.
9. Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34:375-377.
10. Edson RS, Brey RH, McDonald TJ, Terrell CL, McCarthy JT, Thibert JM: Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004;79:1185-1191.
11. Ahya VN, Doyle AM, Mendez JD, Lipson DA, Christie JD, Blumberg EA, Pochettino A, Nelson L, Bloom RD, Kotloff RM: Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant 2005;24:932-935.
12. Scheenstra RJ, Heijerman HG, Touw DJ, Rijntjes E: Cochleotoxicity of systemically administered tobramycin in Cystic Fibrosis patients. J Cyst Fibros 2007;6:S94.
13. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW: Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003;123:28-36.
14. Quanjer PH, Tammeling, GJ, Cotes, JE, Pedersen, OF, Peslin, R, Yernault, JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;6:5-40.
15. Touw DJ, de Graaf AI, de Goede P: Evaluation of a fluorescence polarographic immunoassay with increased sensitivity for measurement of low concentrations of tobramycin in serum. Ther Drug Monit 1996;18:189-193.
16. Asmus MJ, Stewart BA, Milavetz G, Teresi ME, Han SH, Wang D, Ahrens RC: Tobramycin as a pharmacologic tracer to compare airway deposition from nebulizers. Pharmacotherapy 2002;22:557-563.
17. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C: Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007.
18. Cooney GF, Lum BL, Tomaselli M, Fiel SB: Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 1994;34:255-259.
19. Steinkamp G, Tummler B, Gappa M, Albus A, Potel J, Doring G, von der Hardt H: Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6:91-98.
20. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW: A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest 1997;111:955-962.
21. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW: Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122:219-226.
22. Chuchalin A, Csiszer E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H: A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 2007;9(Suppl 1):21-31.
23. Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL: Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 2007;9(Suppl 1):11-20.
24. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A: Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet 2005;365:573-578.
25. Proost JH, Meijer DKF: MW\Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155-163.
26. Jelliffe RW: Estimation of creatinine clearance when urine cannot be collected. Lancet 1971;i:975-976.
27. Touw DJ, Jacobs FA, Brimicombe RW, Heijerman HG, Bakker W, Briemer DD: Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997;41:184-187.
28. Ng PK: Determining aminoglycoside dosage and blood levels using a programmable calculator. Am J Hosp Pharm 1980;37:225-231.
29. Le Brun PP, Vinks AA, Touw DJ, Hekelaar N, Mannes GP, Brimicombe RW, Frijlink EH, Heijerman HG: Can tobramycin inhalation be improved with a jet nebulizer? Ther Drug Monit 1999;21:618-624.
30. Le Brun PPH, Mannes GPM, Brimicombe RW, Frijlink HW, Heijerman HGM: Pharmacokinetic modelling of tobramycin after high dose inhalation in patients with cystic fibrosis. In: Optimization of Antibiotic Inhalation Therapy in Cystic Fibrosis. Studies on Nebulized Tobramycin. Development of a Colistin Dry Powder Inhaler System. Thesis Rijksuniversiteit Groningen, The Netherlands 2001.
31. Weber A, Smith A, Hack B, Williams-Warren J, Ramsey B, Unadkat J: Tobramycin serum pharmacokinetics after aerosol administration. Pediatr Pulmonol 1989;s4:136.
32. Mukhopadhyay S, Baer S, Blanshard J, Coleman M, Carswell F: Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis. J Antimicrob Chemother 1993;31:429-436.
33. Poli G, Acerbi D, Pennini R, Soliani Raschini A, Corrado ME, Eichler HG, Eichler I: Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Paediatr Drugs 2007;9(Suppl 1):3-9.
34. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, Weers JG: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003;124:360-366.
35. Neu HC: Tobramycin: an overview. J Infect Dis 1976;134(Suppl):S3-S19.
36. Bennett WD, Smaldone GC: Human variation in the peripheral air-space deposition of inhaled particles. J Appl Physiol 1987;62:1603-1610.
37. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Doring G, von der Hardt H: Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92.
38. Novartis Pharmaceuticals Canada Inc. Q, Canada. Prescribing information PrTOBI*. 2006.
39. Chua HL, Collis GG, Le Souef PN: Bronchial response to nebulized antibiotics in children with cystic fibrosis. Eur Respir J 1990;3:1114-1116.
40. Ramagopal M, Lands LC: Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatr Pulmonol 2000;29:366-370.
41. Alothman GA, Alsaadi MM, Ho BL, Ho SL, Dupuis A, Corey M, Coates AL: Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002;122:930-934.
42. Nikolaizik WH, Trociewicz K, Ratjen F: Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2002;20:122-126.
43. Marshall BG, Wangoo A, Harrison LI, Young DB, Shaw RJ: Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid. Eur Respir J 2000;15:764-770.